Ursodeoxycholic Acid for Acute Viral Hepatitis Jaundice
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests whether a medication called ursodeoxycholic acid helps lower bilirubin (a substance that causes yellowing of the skin and eyes) in patients with acute viral hepatitis. The goal is to see if this treatment can reduce jaundice and help patients recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old
- You have acute viral hepatitis (a sudden liver infection caused by a virus)
- Your bilirubin levels are elevated (causing jaundice or yellowing)
- You do not have Hepatitis B or C
- You do not have liver cancer, bile duct disease, or gallstones blocking your bile ducts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a medicine called Ursodeoxycholic Acid (UDCA) to standard light therapy (phototherapy) helps treat newborn jaundice more quickly. Jaundice causes yellow skin and eyes, and this trial looks at babies whose jaundice is severe enough to need light treatment.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial tests whether giving ursodeoxycholic acid (a bile acid medication) after a living donor liver transplant helps the new liver grow and work better. It may help your liver recover more quickly.
This trial tests if giving a zinc or bile acid medicine alongside light therapy helps break down jaundice faster in newborns. It could shorten treatment time for babies who need phototherapy in their first week of life.
This trial tests whether ursodeoxycholic acid (a bile medicine) can help prevent complications from gallstone-related acute pancreatitis from coming back after you leave the hospital. It may help reduce repeat problems linked to gallstones, especially after an initial pancreatitis episode.
This trial tests a new medicine called larsucosterol to see if it helps people with severe alcohol-related hepatitis (liver inflammation from heavy drinking). If you qualify, the study will monitor your safety and recovery over 90 days.
Hear when a new Hepatitis A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.